1-3 of 3
Ralph F. Alderson
Close
Sort by
Journal Articles

Modeling Flotetuzumab-Associated CRS in AML Using in Vitro and in Vivo Preclinical Models

Dilan Anil Patel, Ezhilarasi Chendamarai, Julie K. Ritchey, Michael P. Rettig, Leah Gehrs, Paul Moore, Ralph F. Alderson, Ezio Bonvini, Matthew Christopher, John F. DiPersio
Journal: Blood
Blood (2022) 140 (Supplement 1): 8795–8796.
https://doi.org/10.1182/blood-2022-156943
Published: 2022
Journal Articles

Combinatorial Anti-Tumor Activity in Animal Models of a Novel CD123 x CD3 Bispecific Dart® Molecule (MGD024) with Cytarabine, Venetoclax or Azacitidine Supports Combination Therapy in Acute Myeloid Leukemia

Ralph F. Alderson, Ling Huang, Xiaoyu Zhang, Haiquan Li, Thomas Kaufman, Gundo Diedrich, Paul Moore, Ezio Bonvini
Journal: Blood
Blood (2021) 138 (Supplement 1): 1165.
https://doi.org/10.1182/blood-2021-153192
Published: 2021
Journal Articles

A Next-Generation Fc-Bearing CD3-Engaging Bispecific DART ® Platform with Extended Pharmacokinetic and Expanded Pharmacologic Window: Characterization As CD123 x CD3 and CD19 x CD3 DART Molecules

Ezio Bonvini, MD, Ross La Motte-Mohs, PhD, Ling Huang, Chia-Ying Kao Lam, PhD, Thomas Kaufman, Liqin Liu, PhD, Ralph F. Alderson, PhD, Kurt Stahl, Jennifer G. Brown, PhD, Hua Li, Sharad Sharma, PhD, James Tamura, PhD, Syd Johnson, PhD, Paul Moore, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5230.
https://doi.org/10.1182/blood-2018-99-116264
Published: 2018